Little was known about the branch of epigenetics called histone methyltransferases (HMTs) when Epizyme began in late 2007. Yet before the company presented the world’s first animal demonstration of efficacy for HMTs in July 2011, it had already attracted USD 54 million in venture investment and USD 45 million in funding from two pharma partners and two foundations. Read more »
In January this year, Forma Therapeutics announced two conventional agreements for assets spinning out of its innovative discovery platform that aim for high-risk targets but hold high-reward valuations, potentially totaling USD 1.45 billion in milestone payments. Read more »
The news from Foundation Medicine could not be more encouraging for the company, nor more disruptive for the universe of oncology as we know it today. Read more »
John Brooks has lit a fire under the Joslin Diabetes Center. Over the past year a string of announcements has flowed from the traditionally understated 114-year-old institution. Read more »
Opportunities for acquiring external assets may move faster than an internal BD group can react. Inova supports a capability to be both fast and nimble in the hunt for novel assets from scouting through to licensing and beyond to alliance management. Read more »
The chairmen of Johnson & Johnson Pharmaceuticals and GlaxoSmithKline R&D announced a trailblazing venture fund for fast-tracking early stage assets during the closing plenary session at BIO-Europe Spring® in Amsterdam. Read more »
The biotech sector continues to outperform other industries in public equity markets in the United States, but private equity is more selective about opportunities, according to Biotechnology Industry Organization (BIO). Read more »
Strategic Science & Technologies, LLC (SST) has developed a transformational and potentially disruptive technology that successfully delivers charged therapeutic molecules transdermally. That capability has been the holy grail of transdermal drug delivery. Read more »
Newsletter